Deutsche Bank Starts ARIAD Pharmaceuticals (ARIA) at Hold
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Deutsche Bank initiated coverage on ARIAD Pharmaceuticals (NASDAQ: ARIA) with a Hold rating and a price target of $9.50.
Analyst Andrew Peters said, "The pricing controversy in biopharma has recently hit Ariad, and hence we believe headline risk could overshadow any positive pipeline newsflow until the issue is resolved. Further, while we view ARIA as one of the most fundamentally solid companies in biotech with two commercial (or soon to be commercial) oncology assets, we expect shares to be range-bound in the nearterm as headline risk is weighed against the lack of clear value drivers over the next 12months. That said, we are positive on the company's longer-term fundamentals and its prospects for upside catalysts beyond that timeframe."
Shares of ARIAD Pharmaceuticals closed at $9.01 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alibaba (BABA) PT Raised to $148 at Deutsche Bank
- Halliburton (HAL) PT Lowered to $60 at Credit Suisse; Reiterates Outperform
- Jefferies Reiterastes Hold on McDonald's (MCD) Following 4Q Report
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View, New Coverage
Related EntitiesDeutsche Bank
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!